The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade

Molecular Genetics and Metabolism

Volumn 109, Issue 2, 2013, Pages 183-193

  Xing, Elizabeth M ^a   Knox, Van W ^b   O'Donnell, Patricia A ^b   Sikura, Tracey ^b   Liu, Yuli ^a   Wu, Susan ^a   Casal, Margret L ^b   Haskins, Mark E ^b   Ponder, Katherine P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Glucuronidase; Dog; Dysostosis multiplex; Gene therapy; Mucopolysaccharidosis; Retroviral vector

Indexed keywords

BETA GLUCURONIDASE; RETROVIRUS VECTOR;

ACETABULUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BONE DISEASE; BONE DYSPLASIA; BONE EROSION; DOG; ENZYME ACTIVITY; FEMALE; FEMUR; FEMUR OSTEOTOMY; GAIT DISORDER; GENE THERAPY; HISTOCHEMISTRY; HISTOPATHOLOGY; HYPERPLASIA; JOINT RADIOGRAPHY; MALE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; OSTEOPHYTE; PATELLA; PRIORITY JOURNAL; SYNOVIAL FLUID;

ANIMALS; ANIMALS, NEWBORN; DOGS; FEMALE; FEMUR HEAD; GENETIC THERAPY; GLUCURONIDASE; HINDLIMB; JOINT CAPSULE; JOINTS; MALE; MUCOPOLYSACCHARIDOSIS VII; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 84878515331     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.03.013     Document Type: Article

References (60)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Moore D., Connock M.J., Wraith E., Lavery C. The prevalence of and survival in mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J. Rare Dis. Sep 16 2008, 3:24.
3. White K.K., Harmatz P. Orthopedic management of mucopolysaccharide disease. J. Pediatr. Rehabil. Med. 2010, 3:47-56.
4. White K.K. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50(Suppl. 5):v26-v33.
5. Masterson E.L., Murphy P.G., O'Meara A., Moore D.P., Dowling F.E., Forgarty E.E. Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J. Pediatr. Orthop. 1996, 16:731-733.
6. Field R.E., Buchanan J.A., Copplemans M.G., Aichroth R.W. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J. Bone Joint Surg. Br. 1994, 76:975-981.
7. Taylor C., Brady P., O'Meara A., Moore D., Dowling F., Fogarty E. Mobility in Hurler syndrome. J. Pediatr. Orthop. 2008, 28:163-168.
8. Weisstein J.S., Delgado E., Steinbach L.S., Hart K., Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J. Pediatr. Orthop. 2004, 24:97-101.
9. Montano A.M., Tomatsu S., Gottesman G.S., Smith M., Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J. Inherit. Metab. Dis. 2007, 30:165-174.
10. Valayannopoulos V., Nicely H., Harmatz P., Turbeville S. Mucopolysaccharidosis VI. Orphanet J. Rare Dis. 2010, 5(5):1-20.
11. Muenzer J., Beck M., Eng C.M., Escolar M.L., Giugliani R., Guffon N.H., Harmatz P., Kamin W., Kampmann C., Koseoglu S.T., Link B., Martin R.A., Molter D.W., Muñoz Rojas M.V., Ogilvie J.W., Parini R., Ramaswami U., Scarpa M., Schwartz I.V., Wood R.E., Wraith E. Multidisciplinary management of Hunter syndrome. Pediatrics 2009, 124:e1228-e1239.
12. White K.K., Karol L.A., White D.R., Hale S. Musculoskeletal manifestations of Sanfilippo Syndrome (mucopolysaccharidosis type III). J. Pediatr. Orthop. 2011, 31:594-598.
13. Arn P., Wraith J.E., Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J. Pediatr. 2009, 154(859-864):e853.
14. Sly W.S., Quinton B.A., McAlister W.H., Rimoin D.L. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J. Pediatr. 1973, 82:249-257.
15. Beaudet A.L., DiFerrante N.M., Ferry G.D., Nichols B.L., Mullins C.E. Variation in the phenotypic expression of beta-glucuronidase deficiency. J. Pediatr. 1975, 86:388-394.
16. Vogler C., Levy B., Kyle J.W., Sly W.S., Williamson J., Whyte M.P. Mucopolysaccharidosis VII: postmortem biochemical and pathological findings in a young adult with beta-glucuronidase deficiency. Mod. Pathol. 1994, 7:132-137.
17. de Kremer R.D., Givogri I., Argarana C.E., Hliba E., Conci R., Boldini C.D., Capra A.P. Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a chronic variant with an oligosymptomatic severe skeletal dysplasia. Am. J. Med. Genet. 1992, 44:145-152.
18. Smith L.J., Baldo G., Wu S., Liu Y., Whyte M.P., Giugliani R., Elliott D.M., Haskins M.E., Ponder K.P. Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII. Mol. Genet. Metab. 2012, 107:153-160.
19. Rowan D.J., Tomatsu S., Grubb J.H., Montaño A.M., Sly W.S. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J. Inherit. Metab. Dis. 2013, 36:235-246.
20. Guiral J., Sanchez J.M., Gonzalez M.A. Stress fracture of the femoral neck in a young adult with Maroteaux-Lamy syndrome. Acta Orthop. Belg. 1992, 58:91-92.
21. Baz A.B., Akalin S., Arik H., Ergün A. Proximal realignment surgery for unilateral chronic patella dislocation in Morquio syndrome: a case report. Acta Orthop. Traumatol. Turc. 2011, 45:466-469.
22. Baldo G., Wu S., Howe R.A., Ramamoothy M., Knutsen R.H., Fang J., Mecham R.P., Liu Y., Wu X., Atkinson J.P., Ponder K.P. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol. Genet. Metab. 2011, 104:608-619.
23. Simonaro C.M. Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation. J. Pediatr. Rehabil. Med. 2010, 3:85-88.
24. Simonaro C.M., D'Angelo M., Haskins M.E., Schuchman E.H. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res. 2005, 57:701-707.
25. Ausseil J., Desmaris N., Bigou S., Attali R., Corbineau S., Vitry S., Parent M., Cheillan D., Fuller M., Maire I., Vanier M.T., Heard J.M. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 2008, 3:e2296.
26. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008, 172:112-122.
27. Johnson G.B., Brunn G.J., Kodaira Y., Platt J.L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 2002, 168:5233-5239.
28. Lai A., Simonaro C.M., Schuchman E.H., Ge Y., Laudier D.M., Iatridis J.C. Structural, compositional, and biomechanical alterations of the lumbar spine in rats with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). J. Orthop. Res. 2013, 31:621-631.
29. Metcalf J.A., Linders B., Wu S., Bigg P., O'Donnell P., Sleeper M.M., Whyte M.P., Haskins M., Ponder K.P. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol. Genet. Metab. 2010, 99:396-407.
30. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:222-227.
31. Smith L.J., Martin J.T., Szczesny S.E., Ponder K.P., Haskins M.E., Elliott D.M. Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII. J. Orthop. Res. 2010, 28:616-622.
32. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50(Suppl. 5):v49-v59.
33. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010, 62:33-40.
34. van der Linden M.H., Kruyt M.C., Sakkers R.J., de Koning T.J., Oner F.C., Castelein R.M. Orthopaedic management of Hurler's disease after hematopoietic stem cell transplantation: a systematic review. J. Inherit. Metab. Dis. 2011, 34:657-669.
35. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., Okazaki S., Huff K., Cox G.F., Swiedler S.J., Kakkis E.D. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6years. Mol. Genet. Metab. 2007, 90:171-180.
36. White K.K., Hale S., Goldberg M.J. Musculoskeletal health in Hunter disease (MPS II): ERT improves functional outcomes. J. Pediatr. Rehabil. Med. 2010, 3:101-107.
37. Harmatz P., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Plecko B., Steiner R., Whitley C.B., Kaplan P., Yu Z.F., Swiedler S.J., Decker C. MPS VI study group, long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Genet. Metab. 2008, 94:469-475.
38. Furujo M., Kubo T., Kosuga M., Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol. Genet. Metab. 2011, 104:597-602.
39. McGill J.J., Inwood A.C., Coman D.J., Lipke M.L., de Lore D., Swiedler S.J., Hopwood J.J. Enzyme replacement therapy for mucopolysaccharidosis VI from 8weeks of age - a sibling control study. Clin. Genet. 2010, 77:492-498.
40. Ponder K.P., Haskins M.E. Gene therapy for mucopolysaccharidosis. Expert. Opin. Biol. Ther. 2007, 7:1333-1345.
41. Xu L., Haskins M.E., Melniczek J.R., Gao C., Weil M.A., O'Malley T.M., O'Donnell P.A., Mazrier H., Ellinwood N.M., Zweigle J., Wolfe J.H., Ponder K.P. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol. Ther. 2002, 5:141-153.
42. Ponder K.P., Melniczek J.R., Xu L., Weil M.A., O'Malley T.M., O'Donnell P.A., Knox V.W., Aguirre G.D., Mazrier H., Ellinwood N.M., Sleeper M., Maguire A.M., Volk S.W., Mango R.L., Zweigle J., Wolfe J.H., Haskins M.E. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13102-13107.
43. Herati R.S., Knox V.W., O'Donnell P., D'Angelo M., Haskins M.E., Ponder K.P. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol. Genet. Metab. 2008, 95:142-151.
44. Mango R.L., Xu L., Sands M.S., Vogler C., Seiler G., Schwarz T., Haskins M.E., Ponder K.P. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol. Genet. Metab. 2004, 82:4-19.
45. Smith L.J., Martin J.T., O'Donnell P., Wang P., Elliott D.M., Haskins M.E., Ponder K.P. Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs. Mol. Genet. Metab. 2012, 107:145-152.
46. Traas A.M., Wang P., Ma X., Tittiger M., Schaller L., O'donnell P., Sleeper M.M., Vite C., Herati R., Aguirre G.D., Haskins M., Ponder K.P. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol. Ther. 2007, 15:1423-1431.
47. Ponder K.P., O'Malley T.M., Wang P., O'Donnell P.A., Traas A.M., Knox V.W., Aguirre G.A., Ellinwood N.M., Metcalf J.A., Wang B., Parkinson-Lawrence E.J., Sleeper M.M., Brooks D.A., Hopwood J.J., Haskins M.E. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats. Mol. Ther. 2012, 20:898-907.
48. Haskins M., Casal M., Ellinwood N.M., Melniczek J., Mazrier H., Giger U. Animal models for mucopolysaccharidoses and their clinical relevance. Acta Paediatr. Suppl. 2002, 91:88-97.
49. Haskins M.E., Desnick R.J., DiFerrante N., Jezyk P.F., Patterson D.F. Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr. Res. 1984, 18:980-984.
50. Ray J., Scarpino V., Laing C., Haskins M.E. Biochemical basis of the beta-glucuronidase gene defect causing canine mucopolysaccharidosis VII. J. Hered. 1999, 90:119-123.
51. Solau-Gervais E., Zerimech F., Lemaire R., Fontaine C., Huet G., Flipo R.M. Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 2007, 36:373-377.
52. Jorgensen I., Kos J., Krasovec M., Troelsen L., Klarlund M., Jensen T.W., Hansen M.S., Jacobsen S. Serum cysteine proteases and their inhibitors in rheumatoid arthritis: relation to disease activity and radiographic progression. Clin. Rheumatol. 2011, 30:633-638.
53. Eliyahu E., Wolfson T., Ge Y., Jepsen H.J., Schuchman E.H., Simonaro C.M. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One 2011, 6:e22447.
54. Mort J.S., Magny M.C., Lee E.R. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem. J. 1998, 335:491-494.
55. Fosang A.J., Neame P.J., Last K., Hardingham T.E., Murphy G., Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J. Biol. Chem. 1992, 267:19470-19474.
56. Stattin E.L., Wiklund F., Lindblom K., Onnerfjord P., Jonsson B.A., Tegner Y., Sasaki T., Struglics A., Lohmander S., Dahl N., Heinegård D., Aspberg A.A. A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. Am. J. Hum. Genet. 2010, 86:126-137.
57. Kamata Y., Tanabe A., Kanaji A., Kosuga M., Fukuhara Y., Li X.K., Suzuki S., Yamada M., Azuma N., Okuyama T. Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther. 2003, 10:406-414.
58. Daly T.M., Ohlemiller K.K., Roberts M.S., Vogler C.A., Sands M.S. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 2001, 8:1291-1298.
59. Macsai C.E., Derrick-Roberts A.L., Ding X., Zarrinkalam K.H., McIntyre C., Anderson P.H., Anson S.D., Byers S. Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII. Mol. Genet. Metab. 2012, 106:202-213.
60. Wu C., Dunbar C.E. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Front. Med. 2011, 5:356-371.